CTSO.OQ
Latest Trade
8.58USDChange
-0.24(-2.72%)Volume
75,612Today's Range
-
8.8852 Week Range
-
11.74As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 8.82 |
|---|---|
Open | 8.79 |
Volume | 75,612 |
3M AVG Volume | 5.70 |
Today's High | 8.88 |
Today's Low | 8.54 |
52 Week High | 11.74 |
52 Week Low | 3.61 |
Shares Out (MIL) | 43.18 |
Market Cap (MIL) | 380.81 |
Forward P/E | -38.36 |
Dividend (Yield %) | -- |
Cytosorbents- Prelim 2020 Unaudited Total Revenue Was About $40.8 Mln Vs $24.9 Mln In 2019
Cytosorbents Reports Preliminary Q4 And Full Year 2020 Revenue
CytoSorbents Pays Off $15M Term Loans and Establishes New Undrawn $15M Loan Commitment with Bridge Bank
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.
Industry
Medical Equipment & Supplies
Executive Leadership
Al W. Kraus
Independent Non-Executive Chairman of the Board
Phillip P. Chan
President, Chief Executive Officer, Director
Kathleen P. Bloch
Chief Financial Officer
Vincent J. Capponi
Chief Operating Officer
Michael G. Bator
Independent Director
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 10.44 |
Price To Book (MRQ) | 4.75 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 18.89 |
LT Debt To Equity (MRQ) | 7.47 |
Return on Investment (TTM) | -20.90 |
Return on Equity (TTM) | -16.71 |
* CYTOSORB® ADDS BILIRUBIN AND MYOGLOBIN REDUCTION TO EUROPEAN UNION APPROVED INDICATIONS FOR USE
* CYTOSORBENTS REPORTS STRONG FIRST QUARTER 2018 FINANCIAL RESULTS
* CYTOSORBENTS ENROLLS FIRST PATIENT INTO PIVOTAL U.S. REFRESH 2-AKI TRIAL USING CYTOSORB® DURING COMPLEX CARDIAC SURGERY Source text for Eikon: Further company coverage:
* CYTOSORBENTS REFINANCES EXISTING DEBT WITH NEW $15 MILLION DEBT FACILITY WITH BRIDGE BANK
* CYTOSORBENTS ACHIEVES RECORD REVENUE AND PRODUCT SALES GROWTH IN 2017
* CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA
* CYTOSORBENTS PRE-ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND ISSUES STOCKHOLDER LETTER
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.